cvs health corp. - CVS

CVS

Close Chg Chg %
80.83 -1.38 -1.71%

Closed Market

79.45

-1.38 (1.71%)

Volume: 6.53M

Last Updated:

Dec 12, 2025, 3:59 PM EDT

Company Overview: cvs health corp. - CVS

CVS Key Data

Open

$80.99

Day Range

78.68 - 81.08

52 Week Range

43.56 - 85.15

Market Cap

$100.25B

Shares Outstanding

1.27B

Public Float

1.27B

Beta

0.48

Rev. Per Employee

N/A

P/E Ratio

211.21

EPS

$0.39

Yield

329.09%

Dividend

$0.67

EX-DIVIDEND DATE

Oct 23, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

7.82M

 

CVS Performance

1 Week
 
5.01%
 
1 Month
 
2.07%
 
3 Months
 
5.92%
 
1 Year
 
60.87%
 
5 Years
 
10.95%
 

CVS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cvs Health Corp. - CVS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
291.94B 322.79B 358.27B 372.69B
Sales Growth
+8.67% +10.57% +10.99% +4.02%
Cost of Goods Sold (COGS) incl D&A
240.06B 268.17B 303.35B 321.41B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.51B 4.25B 4.37B 4.60B
Depreciation
2.25B 2.44B 2.46B 2.57B
Amortization of Intangibles
2.26B 1.81B 1.91B 2.02B
COGS Growth
+9.29% +11.71% +13.12% +5.95%
Gross Income
51.87B 54.61B 54.93B 51.28B
Gross Income Growth
+5.87% +5.29% +0.57% -6.63%
Gross Profit Margin
+17.77% +16.92% +15.33% +13.76%
2021 2022 2023 2024 5-year trend
SG&A Expense
36.93B 38.21B 39.34B 41.36B
Research & Development
- - - -
-
Other SG&A
36.93B 38.21B 39.34B 41.36B
SGA Growth
+5.31% +3.46% +2.97% +5.13%
Other Operating Expense
- - - -
-
Unusual Expense
2.37B 5.80B 994.00M 1.03B
EBIT after Unusual Expense
12.56B 10.60B 14.59B 8.89B
Non Operating Income/Expense
324.00M (2.70B) (777.00M) 196.00M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.47B 2.27B 2.64B 2.94B
Interest Expense Growth
-14.03% -7.98% +16.15% +11.33%
Gross Interest Expense
2.47B 2.27B 2.64B 2.94B
Interest Capitalized
- - - -
-
Pretax Income
10.42B 5.63B 11.17B 6.15B
Pretax Income Growth
+6.65% -45.99% +98.53% -44.97%
Pretax Margin
+3.57% +1.74% +3.12% +1.65%
Income Tax
2.52B 1.46B 2.81B 1.56B
Income Tax - Current - Domestic
2.95B 3.54B 3.48B 2.13B
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(428.00M) (2.08B) (676.00M) (572.00M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
7.90B 4.17B 8.37B 4.59B
Minority Interest Expense
(12.00M) 16.00M 24.00M (28.00M)
Net Income
7.91B 4.15B 8.34B 4.61B
Net Income Growth
+10.04% -47.55% +101.11% -44.70%
Net Margin Growth
+2.71% +1.29% +2.33% +1.24%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
7.91B 4.15B 8.34B 4.61B
Preferred Dividends
- - - -
-
Net Income Available to Common
7.91B 4.15B 8.34B 4.61B
EPS (Basic)
5.997 3.1624 6.4934 3.6648
EPS (Basic) Growth
+9.35% -47.27% +105.33% -43.56%
Basic Shares Outstanding
1.32B 1.31B 1.28B 1.26B
EPS (Diluted)
5.9518 3.136 6.4682 3.6561
EPS (Diluted) Growth
+8.94% -47.31% +106.26% -43.48%
Diluted Shares Outstanding
1.33B 1.32B 1.29B 1.26B
EBITDA
19.45B 20.65B 19.95B 14.52B
EBITDA Growth
+5.92% +6.16% -3.39% -27.22%
EBITDA Margin
+6.66% +6.40% +5.57% +3.90%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 94.167
Number of Ratings 31 Current Quarters Estimate 0.996
FY Report Date 12 / 2025 Current Year's Estimate 6.659
Last Quarter’s Earnings 1.60 Median PE on CY Estimate N/A
Year Ago Earnings 5.42 Next Fiscal Year Estimate 7.172
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 24 19 26 25
Mean Estimate 1.00 2.25 6.66 7.17
High Estimates 1.07 2.47 6.73 7.50
Low Estimate 0.93 2.11 6.59 6.91
Coefficient of Variance 3.53 5.04 0.51 1.69

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 20 20 20
OVERWEIGHT 5 4 4
HOLD 6 6 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Buy

Insider Actions for Cvs Health Corp. - CVS

Date Name Shares Transaction Value
May 20, 2025 Fernando G. Aguirre Director 39,150 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $60.47 per share 2,367,400.50
May 20, 2025 Jeffrey R. Balser Director 11,884 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $60.47 per share 718,625.48
Apr 4, 2025 James D. Clark SVP, Cont & Chief Acct Officer 24,707 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 1,679,581.86
Apr 4, 2025 Prem S. Shah EVP and Group President 112,289 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 James D. Clark SVP, Cont & Chief Acct Officer 11,240 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 764,095.20
Apr 4, 2025 Thomas F. Cowhey EVP and CFO 68,621 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Thomas F. Cowhey EVP and CFO 41,109 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 2,794,589.82
Apr 4, 2025 Thomas F. Cowhey EVP and CFO 50,188 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 3,411,780.24
Apr 4, 2025 Samrat S. Khichi EVP, CPO and General Counsel 68,621 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Samrat S. Khichi EVP, CPO and General Counsel 41,569 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 2,825,860.62
Apr 4, 2025 Samrat S. Khichi EVP, CPO and General Counsel 21,700 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 1,475,166.00
Apr 4, 2025 Heidi B. Capozzi EVP and Chief People Officer 49,906 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Heidi B. Capozzi EVP and Chief People Officer 95,310 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 6,479,173.80
Apr 4, 2025 Tilak Mandadi EVP, Chief Experience & Tech 87,336 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Tilak Mandadi EVP, Chief Experience & Tech 116,257 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 7,903,150.86
Apr 4, 2025 Tilak Mandadi EVP, Chief Experience & Tech 43,503 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 2,957,333.94
Apr 4, 2025 Prem S. Shah EVP and Group President 47,251 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $67.98 per share 3,212,122.98
Apr 4, 2025 Steven H. Nelson EVP and President, Aetna 90,455 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 4, 2025 Steven H. Nelson EVP and President, Aetna 21,329 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $67.98 per share 1,449,945.42
Apr 4, 2025 J. David Joyner President and CEO; Director 226,138 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Cvs Health Corp. in the News

Why neighborhood pharmacies are closing

Retail pharmacies will never be obsolete, according to an analyst. But the industry needs to take a hard look at how many stores are needed and what items they should sell.

CVS Health to cut 2,900 jobs

CVS Health is slashing its headcount by 2,900, or 1% of its total workforce. The layoffs will largely focus on corporate positions, a spokesperson said.